Pages
Products
AAV9-hSyn-Luc

AAV9-hSyn-Luc

Cat.No. :  AAV00533Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00533Z
Description AAV serotype 9 particles express luciferase reporter gene under the control of human synapsin promoter (hSyn) for neuronal specific expression.
Reporter Luc
Serotype AAV Serotype 9
Target Gene Luc
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

The recombinant adeno-associated virus serotype 9 vector (AAV9-hSyn-Luc), expressing firefly luciferase under the control of the human synapsin 1 promoter (hSyn), is a powerful and versatile tool in neuroscience research, combining several key advantages. First, AAV9 is renowned for its exceptional tropism for central nervous system (CNS) cells. Unlike many other AAV serotypes, AAV9 can efficiently cross the blood-brain barrier (BBB) ​​after systemic administration, enabling efficient and widespread transduction of neurons and glial cells in the brain and spinal cord without the need for invasive intracranial injections, although direct CNS delivery remains an option for targeted studies. Second, the human synapsin 1 (hSyn) promoter provides highly specific and robust neuronal expression. Synapsin is a protein primarily expressed in neurons, and the hSyn promoter fragment used in this vector selectively drives transgene expression in neuronal populations, minimizing off-target expression in non-neuronal cells of the CNS, thereby increasing the specificity and relevance of experimental results. Finally, the firefly luciferase (Luc) reporter gene offers a unique advantage: non-invasive, longitudinal bioluminescence imaging (BLI). After transduction, luciferase expression can be repeatedly and quantitatively monitored over time in the same animal using sensitive optical imaging systems after administration of its substrate, D-luciferin.

AAV9-hSyn-Luc has broad applications across various fields of neuroscience. One of its primary uses is in studying neuronal transduction profiles and gene expression dynamics. Researchers use this vector to map the efficiency and specificity of AAV9 (and potentially related capsids) neuronal targeting in different brain regions, developmental stages, or disease models, via various routes of administration (e.g., intravenous, intrathecal, intracerebroventricular, intraparenchymal). The longitudinal nature of BLI allows for detailed studies of how transduction and expression evolve over time (weeks or months), providing crucial data on vector dynamics. Secondly, it is also a valuable tool for developing and validating novel gene therapy strategies for neurological diseases.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Excellent Neural Targeting

With the hSyn promoter, this vector is perfect for targeting neurons specifically, helping us achieve precise optogenetic modulation in our brain slice experiments.

United States

09/05/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction